Researchers reported a CRISPR methylation editing approach that they say rewrites the cancer epigenome toward causal mechanisms. The work focuses on modifying DNA methylation patterns to probe how specific epigenetic changes influence cancer-relevant gene regulation. By shifting from correlative biomarker mapping to targeted methylation control, the study aims to clarify which epigenetic states contribute to malignant phenotypes—an area where distinguishing cause from effect remains a central bottleneck in cancer biology. The findings add to a broader push for CRISPR-based epigenome tools that can be used both as mechanistic discovery platforms and, eventually, as candidates for therapeutic modulation where safe and durable delivery is feasible.